三个高结核负担国家肺结核患者家庭接触者结核感染的危险因素
在莱索托、南非和坦桑尼亚开展横断面研究,纳入342例病原学确诊肺结核患者和964名家庭接触者。家庭接触者结核感染患病率为48.7%,结核病患病率为3.4%,62.2%符合结核病预防性治疗条件;感染风险随年龄、来自莱索托、既往结核史及HIV阴性而升高。
要点
- 家庭接触者结核感染患病率近半,结核病患病率3.4%。
- 年龄增长、来自莱索托、既往结核史及HIV阴性与感染风险升高相关。
- 约三分之二家庭接触者符合预防性治疗条件,或可无需先检测感染。
核心结论
- 近半数≥5岁结核暴露家庭接触者存在结核感染,约三分之二符合结核病预防性治疗条件。
- 在该人群中,未经结核感染检测直接提供预防性治疗可能是合理的。
研究设计与样本
- 横断面研究,2021年7月至2022年9月在莱索托、南非和坦桑尼亚开展。
- 纳入342例微生物学确诊肺结核患者及其964名家庭接触者。
- 家庭接触者用Xpert Ultra筛查结核病,用QuantiFERON-TB-Gold-Plus检测结核感染。
- 采用广义线性模型(稳健标准误)分析结核感染相关因素。
- 依据世界卫生组织标准判定结核病预防性治疗资格。
主要发现
- 家庭接触者中女性占61.9%(597/964),中位年龄18岁(四分位距8-39岁)。
- 结核病患病率为3.4%(25/739;95%CI 2.2%-4.9%)。
- 结核感染患病率为48.7%(348/714;95%CI 45.0%-52.5%)。
- 结核感染风险随年龄每增加1岁而升高(aOR 1.02;95%CI 1.01-1.03)。
- 来自莱索托(aOR 1.82;95%CI 1.04-3.20)、既往结核史(aOR 2.25;95%CI 1.05-4.79)及HIV阴性(aOR 2.30;95%CI 1.31-4.04)与感染风险升高相关。
关键数值与推荐
- 结核感染判定采用QuantiFERON-TB-Gold-Plus检测。
- 结核病预防性治疗资格依据世界卫生组织标准判定。
- 结核病筛查采用Xpert Ultra检测。
临床怎么用
- 对高结核负担国家家庭接触者应评估结核感染与预防性治疗资格。
- 在检测资源有限时,可考虑不经感染检测直接提供预防性治疗。
- 应优先关注年龄较大、有既往结核史及来自高负担地区的家庭接触者。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although tuberculosis preventive therapy guidelines support testing for tuberculosis infection in household contacts (HHCs), this adds operational complexity and cost and has often been abandoned. To understand utility of testing, we determined prevalence and risk factors for tuberculosis infection and tuberculosis preventive therapy eligibility among HHCs. METHODS: In a cross-sectional study conducted from July 2021 to September 2022 in Lesotho, South Africa, and Tanzania, we enrolled people with microbiologically confirmed pulmonary tuberculosis and their HHCs. HHCs were screened and tested for tuberculosis and tuberculosis infection using Xpert Ultra and QuantiFERON-TB-Gold-Plus, respectively. Generalized linear modelling was used to determine factors associated with tuberculosis infection, using robust standard errors. Tuberculosis preventive therapy eligibility was determined using World Health Organization criteria. RESULTS: We enrolled 342 people with pulmonary tuberculosis and 964 HHCs: 61.9% (597/964) were female with a median age of 18 years (interquartile range, 8-39 years). Overall, tuberculosis prevalence was 3.4% (25/739; 95% confidence interval [CI], 2.2%-4.9%), while tuberculosis infection prevalence was 48.7% (348/714; 95% CI, 45.0%-52.5%). Having tuberculosis infection increased with age per year (adjusted odds ratio [aOR], 1.02; 95% CI, 1.01-1.03), being from Lesotho (aOR, 1.82; 95% CI, 1.04-3.20), previous tuberculosis history (aOR, 2.25; 95% CI, 1.05-4.79), and being HIV negative (aOR, 2.30; 95% CI, 1.31-4.04). Overall, 62.2% (518/833; 95% CI, 58.8%-65.5%) were eligible for tuberculosis preventive therapy. CONCLUSIONS: Almost half of tuberculosis-exposed HHCs aged ≥5 years had tuberculosis infection. Approximately two-thirds of HHCs were eligible for tuberculosis preventive therapy, implying that providing tuberculosis preventive therapy without prior testing for tuberculosis infection may be warranted in this population. Further work on cost-effectiveness is warranted when new tests become available. CLINICAL TRIALS REGISTRATION: ISRCTN10003903.
引用
- Ntshiqa T, Nagudi J, Hamada Y, et al. Risk Factors Associated With Tuberculosis Infection Among Household Contacts of Patients With Microbiologically Confirmed Pulmonary Tuberculosis in 3 High Tuberculosis Burden Countries. J Infect Dis. 2025. PMID: 40576297. doi:10.1093/infdis/jiaf320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。